Clinical Trial Update: A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A single-arm Phase II clinical trial evaluating docetaxel combined with nimotuzumab and pucotenlimab as second-line and beyond therapy for recurrent/metastatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Nimotuzumab (nimotuzumab)
• Pucotenlimab

Snippet

Sponsor: Sun Yat-sen University | Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING